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Available online 9 July 2019Background: The Systematic COronary Risk Evaluation –Older Persons (SCORE-OP) algorithm is developed to as-
sess 10-year risk of death due to cardiovascular disease (CVD) in individuals aged ≥65 years.We studied the per-
formance of SCORE-OP in the European Prospective Investigation of Cancer Norfolk (EPIC-Norfolk) prospective
population cohort.
Methods: 10-year CVD mortality as predicted by SCORE-OP was compared with observed CVD mortality among
individuals in the EPIC-Norfolk cohort. Persons aged 65–79 years without known CVDwere included in the anal-
ysis. CVD mortality was deﬁned as death due to ischemic heart disease, cardiac failure, cerebrovascular disease,
peripheral-artery disease or aortic aneurysm. Predicted 10-year CVD mortality was calculated by the SCORE-OP
algorithm, and compared to observed mortality rates. The area under the receiver operator characteristics curve
(AUROC)was calculated to evaluate discriminative power. Calibrationwas evaluated by calculating ratios of pre-
dicted vs observed mortality and by Hosmer-Lemeshow tests.
Results:A total of 6590 individuals (45.8%men),mean age 70.2 years (standard deviation 3.3)were included. The
predicted mortality by SCORE-OP was 9.84% (95% conﬁdence interval (CI) 9.76–9.92) and observed mortality
was 10.2% (95% CI 9.52–11.04), ratio 0.96. AUROC was 0.63 (95% CI 0.60–0.65), and X2 was 3.3 (p= 0.92).
Conclusion: SCORE-OP overall accurately estimates the rate of CVD mortality in a general population aged 65–
79 years. However, while calibration is excellent, the discriminative power of the SCORE-OP is limited, and as
such cannot be readily implemented in clinical practice for this population.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Aged1. Introduction
In the next decades, the population of individuals aged 65 years and
older will grow until 17% of the world's total population [1]. It is pre-
dicted that the global burden of cardiovascular diseases (CVD) will in-
crease proportionally in this group [2]. While the effect of primary
prevention is well documented in the younger population, there is in-
creasing evidence that older individuals also beneﬁt from primary pre-
vention of CVD [3].
The European guideline on CVD prevention recommends using
SCORE (Systematic COronary Risk Evaluation) as a decision-making
tool in primary prevention [4]. However, the original SCORE chartsesearch, AmsterdamUniversity
, the Netherlands.
eliability and freedom from bias
. This is an open access article underwere only developed and validated in individuals up to 65 years of age
and not validated for individuals older than 65 years. Recently, Cooney
et al. derived and validated a risk assessment function, SCORE-OP
(Older Persons) for individuals over 65 years of age [5]. This risk assess-
ment functionhas only been externally evaluated in limited analysis in a
small sample of individuals aged 65–69 years [6]. We therefore studied
the performance of the SCORE-OP in the European Prospective Investi-
gation of Cancer Norfolk (EPIC-Norfolk) prospective population study,
a large population-based United Kingdom (UK) cohort with individuals
aged up to 79 years [7].2. Methods
2.1. Study population
For our current analysis, we used data from the EPIC-Norfolk prospective population
study. This cohort consists of men and women aged 39–79 years residing in the county
of Norfolk in the UK. Study details of this cohort have been described elsewhere [7]. Inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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attended a baseline health assessment and completed questionnaires about personal
and family history of lifestyle including smoking status. Participants were asked whether
they had any of the following conditions: diabetesmellitus,myocardial infarction or stroke
(self-reported). Participants were followed-up for cause-speciﬁc mortality.
2.2. Study design
In accordance with the selection criteria of the SCORE-OP algorithm, we included all
participants aged 65–79 years of the EPIC-Norfolk cohort. We excluded those with a his-
tory of CVD (myocardial infarction and stroke) at baseline, and participants with missing
data on SCORE-OP variables. CVDmortality was deﬁned as deathwhere CVDwas coded as
the underlying or contributing cause. CVDwas deﬁned as ischaemic heart disease (ICD-10
codes I20–25), cardiac failure (ICD codes I11, I13 and I50), cerebrovascular disease (ICD-
10 codes I60–I69), peripheral artery disease (ICD-10 codes I70–I79) and aortic aneurysm
(ICD-10 code I71).
2.3. Statistical methods
Baseline characteristics are summarized for men and women and excluded individ-
uals separately by using numbers and percentages for categorical data,mean and standard
deviations (SD) for continuous datawith a normal distribution andmedian and interquar-
tile range for continuous variables with a non-normal distribution. Ourmain parameter of
interest was predicted 10-year CVDmortality as calculated with the SCORE-OP algorithm
compared to observed 10-year CVD mortality [5]. Variables included in the SCORE-OP al-
gorithmare age, sex, systolic blood pressure, smoking status, total cholesterol, HDL choles-
terol and diabetes. Correspondingly, we limited the observedmortality rates in our cohort
to the ﬁrst 10 years with Kaplan-Meier (KM) estimates.We evaluated SCORE-OP by using
ratios of predicted and observed CVD mortality. Discriminative power of SCORE-OP was
evaluated by calculating the area under the receiver operator characteristic curve
(AUROC). The Hosmer-Lemeshow goodness-of-ﬁt test based on chi-square statistics was
performed to assess calibration of the SCORE-OP algorithm. In accordance with the
SCORE-OP charts we stratiﬁed by age and sex subgroups of 65–69, 70–74, 75–79 years.
In addition, we stratiﬁed the study population by groups of 2% increments in SCORE-OP
risk, and analyzed differences of the SCORE-OP performance in these risk groups by calcu-
lating ratios of predicted and observed 10-year CVDmortality. A sensitivity analysis of the
SCORE-OP was performed on normotensive (systolic blood pressure ≤ 140 mmHg) and
hypertensive (systolic blood pressure ≥ 140 mmHg) individuals.
SCORE-OP also provides coefﬁcients for 5-year CVD mortality prediction [5]. We
therefore compared the performance of 5-year SCORE-OPwith observed 5-year CVDmor-
tality (KM estimate), and evaluatedwith ratios of predicted and observedmortality, in ad-
dition to evaluating its discriminative power (AUROC) and calibration (Hosmer-
Lemeshow).
We also compared the predicted 10-year CVD mortality as calculated using SCORE
low-risk with SCORE-OP. Although the SCORE low-risk algorithm has not been developed
and validated for individuals older than 65 years, we evaluated the performance in the
samemanner as SCORE-OP in thedifferent age-sex groups (predicted/observed ratios, dis-
crimination, and calibration) to compare the performance of both algorithms. Differences
in discriminative powerbetween SCORE low-risk and SCORE-OPwere compared using the
C-statistic.
To assess the clinical impact of SCORE-OP on the initiation of preventive therapies, we
calculated the percentage of individuals above the 5% and 10% 10-year CVDmortality risk
threshold for both the SCORE-OP and SCORE low-risk algorithms [4,5].
3. Results
The study population consisted of 8145 participants aged 65–
79 years. A total of 1555 participants were excluded due to a history
of CVD (n = 665), missing data on baseline CVD (n = 13) or missing
data for the SCORE-OP variables (n=877), leaving 6590participants el-
igible for analysis (Fig. 1). Mean agewas 70.2 years (SD 3.3), 45.8%were
men and 8.3% were current smokers. Mean body mass index was
26.5 kg/m2 (SD 3.7), mean total cholesterol was 6.4 mmol/l (SD 1.2),
and mean LDL cholesterol was 4.2 mmol/l (SD 1.1). Excluded cases
showed a 4.3% higher incidence of diabetes mellitus (Table 1).
3.1. Performance of SCORE-OP 10-year predicted cardiovascular mortality
Table 2 presents predicted 10-year CVD mortality according to the
SCORE-OP algorithm and observed 10-year CVD mortality. In the total
population the predicted CVD mortality was 9.84% (95% CI 9.76–9.92)
whereas observed CVD mortality (KM estimate) was 10.2% (95% CI
9.52–11.04), yielding a ratio of 0.96. Goodness-of-ﬁt for the SCORE-OP
algorithm was excellent with a X2 of 3.26, (p = 0.92). Discriminative
performance was limited, with an AUROC of 0.63 (95% CI 0.60–0.65).In men and women, the predicted 10-year CVDmortality versus ob-
served CVDmortality ratio was 0.92 and 1.004, respectively. Goodness-
of-ﬁt for the SCORE-OP algorithm was excellent in both men and
women with a X2 of 13.27, (p = 0.10) and 10.03 (p = 0.26), respec-
tively. Discriminative performance was limited in both groups with an
AUROC of 0.60 (95% CI 0.57–0.63) in men and 0.58 (95% CI 0.54–0.62)
in women.
When analyzed according to age-sex groups, SCORE-OP
underestimated CVD mortality in all groups, with the exception of
men and women aged 65–69 years (Fig. 2). In men and women aged
65–69 years, predicted 10-year CVD mortality versus observed CVD
mortality yielded a ratio of 1.29 and 1.46, respectively. Goodness-of-ﬁt
for the SCORE-OP algorithm in men andwomen aged 65–69was excel-
lent, however discriminative performance was severely limited with an
AUROC of 0.54 (95% CI 0.49–0.60) in men and 0.49 (0.41–0.56) in
women (Table 2). In both men and women aged 70–74 and 75–
79 years, SCORE-OP showed a similar magnitude of underestimation.
In men and women aged 70–74 years, predicted 10-year CVDmortality
versus observed CVD mortality yielded a ratio of 0.78 and 0.85, respec-
tively. Goodness-of-ﬁt for the algorithm showed excellent calibration
with a X2 of 7.93 (p=0.44) inmen and 6.52 (p=0.59) in women. Dis-
criminative performance in men and women of the same age was se-
verely limited with an AUROC of 0.52 (95% CI 0.47–0.56) and 0.46
(0.41–0.52). In men and women aged 75–79 years, predicted 10-year
CVDmortality versus CVDmortality yielded a ratio of 0.73 and 0.66, re-
spectively. Goodness-of-ﬁt for the algorithm remained excellent, with a
X2 of 2.66, (p= 0.95) in men and 6.28 (p= 0.62) in women while dis-
criminative performance was severely limited with an AUROC of 0.47
(95% CI 0.39–0.55) in men 0.55 (95% CI 0.46–0.65) in women.
e-Fig. 1 presents the ratios of predicted 10-year CVD mortality by
SCORE-OP and observed CVD mortality in SCORE-OP risk groups of 2%
increments. Prediction was most accurate in men and women with a
risk score between 8 and 10%, yielding a ratio of 1.02. In the risk group
of 6 to 8% SCORE-OP overestimated risk by 14%, whereas in the other
risk groups it underestimated CVD mortality. In the risk groups of 2 to
4% and 18 to 20%, underestimation was nearly 50%. However, these
groups consisted of a very limited number of individuals (2–4% n =
15, 18–20% n= 29).
In the blood pressure sensitivity analysis, normotensive individuals
(systolic blood pressure ≤ 140 mmHg), had a ratio of predicted versus
observed CVD mortality of 1.21 (AUROC 0.64 (95% CI 0.59–0.68), X2
3.17 (p = 0.92)), and hypertensive individuals (systolic blood
pressure N 140 mmHg) had a ratio 0.83, (AUROC 0.61 (95% CI 0.58–
0.64), X2 13.58 (p= 0.09)).
3.2. Performance of SCORE-OP 5-year predicted cardiovascular mortality
In the population of 65–79 years, SCORE-OP 5-year risk of CVDmor-
tality was 3.35% (95% CI 3.31–3.39) compared to observed CVD mortal-
ity of 3.70% (95% CI 3.20–4.20), yielding a ratio of 0.91. Goodness-of-ﬁt
for the SCORE-OP 5-year risk was excellent with a X2 of 4.49 (p =
0.81). Discriminative performance remained limited with an AUROC of
0.64 (95% CI 0.60–0.68) (Table 2). In men and women, predicted 5-
year CVD mortality versus observed CVD mortality yielded a ratio of
0.90 and 0.93, respectively.
3.3. Performance of the SCORE-OP versus SCORE low-risk in predicting 10-
year cardiovascular mortality
When calculated for the total population aged 65–79 years, SCORE
low-risk performed poorer than SCORE-OP. Predicted CVD mortality
was 7.61% (95% CI 7.49–7.73) whereas observed CVD mortality was
10.20% (95% CI 9.52–11.04), yielding a ratio of 0.75 compared to a
ratio of 0.96 with SCORE-OP. The AUROC was 0.66 (95% CI 0.64–0.69)
vs 0.63 (95% CI 0.60–0.65) and the X2 was 13.65 (p = 0.09) vs a X2 of
3.26 (p = 0.92) in SCORE low-risk and SCORE-OP, respectively. There
Fig. 1. Flow chart, study population.
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(X2 9.97) (p ≤ 0.01). SCORE low-risk also performed poorer compared
to SCORE-OP in men andwomen separately with SCORE low-risk ratios
of 0.67 and 0.83 and SCORE-OP ratios of 0.92 and 1.00, respectively.
However, in the age subgroup of 65–69 years, SCORE low-risk per-
formed better compared with SCORE-OP (ratio 0.90 vs 1.36, AUROC
0.66 (95% CI 0.60–0.73) vs 0.59 (95% CI 0.55–0.63), X2 9.09 (p= 0.34)
vs 7.98 (p=0.44)). In individuals 70–79 years, SCORE-OPwas superior
to the SCORE low-risk algorithm with ratios of 0.82 vs 0.69 in men and
women of 70–74 years and 0.65 vs 0.61 in men and women of 75–
79 years.
3.4. Treatment thresholds
According to SCORE-OP, 98% (6468/6590) of all older (65–79 years)
individuals had a 10-yearmortality risk of ≥5%. According to SCORE low-
risk a risk of ≥5% was observed in 67% (4391/6590). Above 70 years of
age this percentage was 100% according to SCORE-OP whereas in
SCORE low-risk the percentages for individuals of 70–74 years and
75–79 years were 83% (2172/2622) and 96% (625/649), respectively.Table 1
Population characteristics.
Total
(n= 6590)
Men
(n= 3016)
Women
(n= 3574)
Age, years 70.2 ± 3.3 70.3 ± 3.3 70.2 ± 3.3
Weight, kg 72.3 ± 12.6 78.7 ± 11.0 66.8 ± 11.1
Body mass index, kg/m2 26.5 ± 3.7 26.5 ± 3.2 26.5 ± 4.1
Current smokers 8.3% (544) 9.3% (297) 7.4% (265)
Systolic blood pressure, mmHg 143.8 ± 18.6 144.2 ± 18.7 143.5 ± 18.6
Diastolic blood pressure, mmHg 84.6 ± 11.5 85.3 ± 11.7 84.0 ± 11.3
Total cholesterol, mmol/l 6.4 ± 1.2 6.0 ± 1.1 6.7 ± 1.2
LDL cholesterol, mmol/l 4.2 ± 1.1 3.9 ± 1.0 4.4 ± 1.1
HDL cholesterol, mmol/l 1.4 ± 0.4 1.2 ± 0.3 1.6 ± 0.4
Triglycerides, mmol/l 1.6 [0.3–7.5] 1.7 [0.3–7.5] 1.6 [0.4–6.9]
Diabetes mellitusa, % 207 (3.1) 130 (4.3) 77 (2.2)
Abbreviations: kg, kilogram; m2, square meter; mmHg, millimeter mercury; mmol/l, mil-
limole per liter; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Note: Data are presented as mean ± standard deviation, median and [IQR] or number
(percentage).
a Self-reported.With a cut-off point of ≥10% risk of 10-year mortality, 41% (2708/
6590) of all older individuals were above this level according to
SCORE-OP in contrast to 22% (1466/6590) according to SCORE low-risk.
4. Discussion
In this validation study of the SCORE-OP algorithm in the EPIC-
Norfolk cohort, we found that in a general population aged 65–
79 years, SCORE-OP overall accurately estimates the rate of CVDmortal-
ity. While calibration was excellent, discriminative power was limited,
both for the prediction of 5- and 10-year CVD mortality. When looking
at sexes separately, point estimates of predicted and observed 10-year
CVD mortality were accurate, the algorithm well-calibrated, but dis-
criminative power markedly limited. Respectively, SCORE-OP over-
and underestimated in the younger (65–69) and older (70–79) age-
sex groups. These aspects should be addressed before widespread use
of SCORE-OP in clinical practice is recommended.
SCORE-OP is developed for individual CVD risk prediction [5]. There-
fore, the limited discrimination in our external validation study war-
rants attention. In the original paper by Cooney et al., discriminative
performance showed an AUROC of 0.74 in the overall population of
20,825 European individuals aged 65 years and over, andwas compara-
ble with their simulated external validation, which also reported an
AUROC of 0.74 [5]. This is in contrast to our ﬁndings showing an
AUROC of 0.63 in the overall population aged 65–79 years. Several fac-
tors could have inﬂuenced our contrasting ﬁndings. First, when analyz-
ing our data according to age-sex subgroups, we found a complex
interplay between predicted and observed CVDmortality. In individuals
aged 65–69 years, SCORE-OP overestimated 10-year CVD mortality,
whereas in individuals aged 70–79 years a considerable underestima-
tion was observed. Second, a well ﬁtted model can have poor discrimi-
nation [8]. This is due to the inﬂuence of population disease
prevalence on which themodel is developed and the individual risk es-
timation which is leading in the discriminative performance. However,
limited discrimination does not translate into low accuracy per se.
Third, in our sensitivity analysis on systolic blood pressure, we found
that SCORE-OP overestimates CVD mortality in normotensive individ-
uals (≤140 mmHg), and underestimates in hypertensive individuals
(N140mmHg), In addition, the discriminative performance was limited
Table 2
Predicted by SCORE-OP and observed 10-year and 5-year CVD mortality, discrimination, and calibration.
N % SCORE-OP % Observed AUROC Hosmer Lemeshow test
CVD mortality 95% CI CVD mortality 95% CI 95% CI Chi square p-Value
10 year
Overall 6590 9.84 9.76–9.92 10.20 9.52–11.04 0.63 0.60–0.65 3.26 0.92
Men 3016 12.70 12.62–12.79 13.80 12.57–15.15 0.60 0.57–0.63 13.27 0.10
Women 3574 7.43 7.39–7.47 7.40 6.53–8.29 0.58 0.54–0.62 10.03 0.26
Age-sex group
Men 65–69 1508 11.26 11.17–11.35 8.70 7.39–10.33 0.54 0.49–0.60 5.24 0.73
Men 70–74 1196 13.78 13.68–13.88 17.60 15.59–20.19 0.52 0.47–0.56 7.93 0.44
Men 75–79 312 15.54 15.34–15.71 21.20 20.22–30.85 0.47 0.39–0.55 2.66 0.95
Women 65–69 1809 6.55 6.50–6.59 4.50 3.60–5.56 0.49 0.41–0.56 12.47 0.13
Women 70–74 1428 8.12 8.07–8.17 9.50 8.07–11.22 0.46 0.41–0.52 6.52 0.59
Women 75–79 337 9.24 9.16–9.32 14.00 10.61–18.37 0.55 0.46–0.65 6.28 0.62
5-year
Overall 6590 3.55 3.31–3.39 3.70 3.25–4.18 0.64 0.60–0.68 4.49 0.81
Men 3016 4.77 4.74–4.81 5.30 4.59–6.22 0.61 0.56–0.65 11.68 0.17
Women 3574 2.15 2.14–2.16 2.30 1.86–2.85 0.51 0.44–0.57 7.48 0.17
Age-sex group
Men 65–69 1508 4.23 4.19–4.26 3.70 2.81–4.74 0.57 0.49–0.65 7.72 0.46
Men 70–74 1196 5.18 5.14–5.22 6.60 5.34–8.22 0.55 0.49–0.62 16.29 0.04
Men 75–79 312 5.85 5.78–5.91 8.90 6.11–12.74 0.49 0.38–0.60 10.27 0.25
Women 65–69 1809 1.89 1.88–1.91 1.50 1.04–2.21 0.46 0.34–0.58 11.05 0.20
Women 70–74 1428 2.35 2.33–2.36 3.30 2.46–4.35 0.39 0.31–0.48 4.37 0.82
Women 75–79 337 2.67 2.65–2.70 2.40 1.21–4.75 0.57 0.37–0.77 2.03 0.98
Abbreviations: N, number; SCORE-OP, Systematic COronary Risk Evaluation Older Persons; CVD; cardiovascular disease; CI, conﬁdence interval.
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uting risk factor into account, themodel does not gain discriminative ac-
curacy. This was also conﬁrmed when SCORE-OP was analyzed
according to separate risk groups. We found that a higher SCORE-OP
risk score does not necessarily lead to more accurate estimation. How-
ever, the ratios of predicted and observed 10-year CVD mortality in
the lower (2–4%) and higher risk groups (16–18% and 18–20%) could
have been inﬂuenced by the low number of included individuals.
The current EuropeanCVDprevention guideline suggests preventive
treatment in case of ≥5% risk of 10-year CVDmortality [4]. When calcu-
lated by the SCORE-OP algorithm, virtually all older individuals (98%)
exceeded the 5% treatment threshold; above 70 years every individual
had a risk ≥5%. Using an arbitrary threshold of 10% risk, this number
was reduced to 41% of the total population [5]. With such exceedingly
high numbers of individuals at high risk, using a risk assessment tool
to determinewhether preventive therapies should be initiated is of lim-
ited added value in clinical practice, and potentially leads to a signiﬁcant
overtreatment of older adults.Fig. 2. Ratios of predicted and observed 10-year CVD mortality. Note: Bars represent the
ratio between predicted 10-year CVD mortality using SCORE-OP algorithm/observed 10-
year CVD mortality by age and sex groups.The majority of studies referred to in the European CVD pre-
vention guideline on preventive treatment were performed in
adults up to 65 years [4]. The treatment recommendations are
therefore not directly transferrable to individuals above 65 years.
The guideline describes the potential beneﬁts of cholesterol lower-
ing therapy in primary prevention in the older population, but ex-
tensive evidence-based recommendations are lacking.
Nevertheless, in secondary prevention treatment beneﬁts of statins
have shown to be similar in elderly (N65 years) as compared to
middle aged individuals [9,10]. In addition, blood pressure treat-
ment in the very old (N80 years) has been found to be beneﬁcial
in reducing the risk of CVD [11]. In a recent study of a nurse-led
multicomponent primary CVD prevention program in older adults
aged 70 to 78 years, positive results on systolic blood pressure
(2.39 mmHg (95% CI 0.87–3.90)) and cigarette smoking −1.85
(95% CI −3.36–0.35) were found in the intervention group [12].
Nevertheless, the intervention did not affect the SCORE-OP risk
proﬁle at six years follow-up. With the increasing possibilities to
predict CVD risk in older adults, there is an increasing need for
thorough evidence on CVD risk factor management to guide clini-
cians in clinical decision making.
In contrast to our ﬁndings, Brotons et al. found that in a Spanish pop-
ulation (N=974) aged 65–69years, SCORE-OP estimated lower rates of
10-year CVD mortality as compared with SCORE low-risk [6]. Our ﬁnd-
ings show a higher risk estimation by SCORE-OP. The contrast in ﬁnd-
ings could be explained by the different statistical approaches, where
Brotons et al. performed an analysis chieﬂy consisting of Kappa values
between both algorithms, whereas we rigorously evaluated the overall
population and relevant subgroups, calculating and comparing both cal-
ibration and discriminative performance.
Although CVDmortality is a hard and currently a leading outcome in
risk estimation models, morbidity is at least as important due to the in-
dividual and societal impact [4,13]. In the current study we focused on
the validation of the SCORE-OP tool for risk estimation of 10-year CVD
mortality, and we did not asses CVD morbidity. We have previously
demonstrated that a complex relationship exists between CVD mortal-
ity and morbidity when analyzed according to age and sex beyond the
scope of the SCORE charts [14]. Ratios of morbidity to mortality are es-
pecially high in younger individuals and in women, but decrease with
increasing age. Therefore, we also do not recommend applying the
230 L. Verweij et al. / International Journal of Cardiology 293 (2019) 226–230ﬁxed multiplier (3×) as suggested by the European CVD prevention
guideline in older individuals to calculate total CVDmorbidity andmor-
tality rates from calculated mortality rates alone [4].
4.1. Strengths and limitations
There are several strengths to our study. First, we used the EPIC-
Norfolk cohort as a representative cohort for low-risk countries accord-
ing to the European Society of Cardiology [15]. Of this cohort, 6590
adults aged 65–79 years were eligible for our study and more than
half of the included individuals were women. Second, we were able to
compare the performance of the SCORE-OP with the current risk algo-
rithm (SCORE low-risk), which has been previously validated in this
population [16]. Finally, we were able provide insight into the nuanced
differences in performance of the SCORE-OP algorithm in the overall
population and in different subgroups, using a thorough statistical
approach.
When interpreting the results of our study, some aspects should be
taken into account. First, we excluded approximately 10% of cases
from the dataset due to missing SCORE-OP variables. We compared de-
mographics in the missing cases with the baseline demographics of in-
cluded cases and except for 4.3% more cases with diabetes mellitus
among excluded cases, we did not ﬁnd signiﬁcant differences. Second,
the prevalence of diabetesmellituswas low in our overall study popula-
tion (3.1%). This can be partly explained by the excluded cases with
missing values on the SCORE-OP algorithm and the exclusion of individ-
uals with a history of CVD. Nevertheless, compared to the prevalence of
diabetes mellitus in the population of the original validation cohort
(7%), our prevalence was lower, which could have inﬂuenced the CVD
risk estimation by the SCORE-OP [5]. Third, the EPIC-Norfolk cohort is
limited to individuals aged up to 79 years, and therefore we were not
able to study the performance of the SCORE-OP in the very old popula-
tion (≥80 years) as was performed in the internal validation study of
Cooney et al. [5]. Fourth, we did not compare our results with the per-
formance of other well known risk algorithms, such as the Framingham
and QRISK2 risk scores, algorithms that have incorporated interaction
terms for age and other risk factors to adjust the risk scores for use in
older adults [13]. This could provide further insight on alternative in-
struments with a more accurate performance in older individuals. Nei-
ther were we able to evaluate the effect of therapeutic strategies
(initiation of lifestyle interventions and drug therapy) on cardiovascular
mortality in our population due to a lack of data on these interventions
after baseline data collection. Finally, although the ICD-10 codes of the
outcomes in our study were mainly similar to the ICD-9 codes that
were included in the original SCORE study, there are a few differences
which could have contributed to a potential lower number of outcome
events in our study [16].
5. Conclusion
The SCORE-OP algorithm overall accurately estimates the rate of
CVD mortality in a general population aged 65–79 years. However,
while calibration was excellent, discriminative power was limited,
both for the 5-year and the 10-year predictions. Therefore, SCORE-OP
cannot readily be implemented in clinical practice in this population.
Further development and testing of the SCORE-OP to improve CVD
risk stratiﬁcation in older individuals is warranted.Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2019.07.020.
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